Drug developpment Drug developpment
logo
Select your search
Contact us
You are here : Viral & Prions Safety

Viral & Prions Safety: Assess the Risk Now!

Viral & Prions Safety Bertin Pharma

Viral & Prions Safety (viral inactivation & viral clearance) including the prions (TSE agent) risk is a major issue for biologics (peptides/proteins, gene therapy, cell therapy, etc.) as well as for blood derivative products.

The first step is to assess the risk on dossier and then, if necessary, to address the experimental phase.

Available methodologies used are for viruses, qPCR or qRT-PCR, infectivity assays and for prions, an in vitro approach using an ultrasensitive western blot and in vivo (bioassay) using the reference model of hamsters infected with the scrapie 263K strain or murine models closer to the risk associated with the variant Creutzfeldt-Jakob Disease (CJD) such as the 6PB1 strain, a BSE strain adapted to mouse. On this topic, Bertin Pharma collaborates with Texcell and Voisin Consulting.

top

Bertin Pharma - Drug developpment

Follow Us

Linkedin Youtube Twitter Google+

Contact us

Any project? Any challenge? We are in!
+33 (0) 139 306 260
Any questions? Contact us

Headquarters:
Parc d’Activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux - France
View our other locations

Newsletter

Do you want to be kept updated with Bertin Pharma's latest news?

Manage my subscriptions